Forestay Capital

Our mission is to establish a partnership with companies worldwide and boost Taiwan’s economic growth. Taiwania Capital is a venture capital that focuses on investing in technologies and biotech areas start-ups that are Taiwan or US-based with disruptive and advanced technology. Taiwania Capital is named after Taiwania cryptomerioides, a unique tree species that took its name from Taiwan in 1906. With heights reaching up to 90 meters, the Taiwania tree is one of the tallest tree species in Asia, and surrounding it is a diverse and vibrant ecosystem. By linking technology and capital, Taiwania Capital aspires to also create a robust ecosystem in Taiwan that is rooted in entrepreneurial innovation.

Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility.

Bio&Tech Smart Capital is the alliance of researchers and entrepreneurs with Venture Capital management professionals to transfer scientific knowledge to society, with the aim of transforming spin off projects and startups that emerge from universities into solid and profitable companies. innovation laboratories and institutions. Investment criteria Bio&Tech Smart Capital focuses its activity focus on: Digital technologies applied to life sciences (focus on automation and data science). Biotechnology. Diagnostics and medical devices. Sustainability. Selected for the combination of: social impact, potential profitability and the experience and knowledge of the sector of the team. Diversification : no sector will represent more than 50% of the invested capital.

Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. As a results-driven organization, we are constantly looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level.

LemVega Capital is a prestigious and elite investment management firm providing investment advisory services and three unique funds to ultra-high-net-worth individuals and institutions. Our firm was established with the objective of assisting investors in achieving their financial goals by offering access to alternative investment opportunities that are typically not available through traditional channels. Headquartered in Puerto Rico and the United States, LemVega Capital™ is registered as an exempt-reporting adviser and is recognized as a distinguished financial institution. As a multi-fund, multi-generational firm, we operate three funds under management, collectively managing a substantial eight-figure assets under management (AUM). Our fund offerings include two cutting-edge hedge funds and an innovative biotech venture capital fund. As a leading firm, LemVega Capital™ leverages advanced technology and time-tested investment strategies to deliver remarkable returns for our clients. Our portfolio comprises a diverse range of investments, including equities, derivatives, currencies, commodities, and groundbreaking biotech offerings. With our unique position as a long & short multi-strategy asset hedge fund, we employ both technical and fundamental analysis, giving us a competitive edge in making astute investment decisions. At the heart of LemVega Capital™, we prioritize transparency, integrity, and delivering results. Our seasoned team of professionals possesses a deep understanding of financial markets and is dedicated to upholding the highest standards of excellence. We have implemented a robust risk management framework to safeguard our clients' capital under all circumstances. Whether you are an institutional investor or a high-net-worth individual, LemVega Capital™ offers a distinctive and compelling investment proposition. Our combination of innovative investment strategies and unwavering commitment to our clients sets us apart in the finance industry.

Fåhraeus Startup and Growth Fund was started in 2021 by Christer Fåhraeus and Emanuel Eriksson. It is a Venture Capital fund focusing on investing early in companies in life science and tech. The goal of the investments is to take the companies up for sale or listing on the stock exchange a few years after the investment. Christer and Emanuel, together with Linus Wiebe, manage the fund. History of the fund In recent years, Christer Fåhraeus and Emanuel Eriksson have worked together with investments in small listed companies and unlisted life science and tech companies for Fårö Capital. Fårö Capital is a Family Office fund where Christer has been CEO and Emanuel Investment Manager. During the years at Fårö Capital, they decided to raise a fund for investments in companies in the same industry with excellent growth potential. Sustainability Fåhraeus Startup & Growth has integrated sustainability risks into the investment decision process at all stages of the investment life cycle. Sustainability risks include environmental, social or governance-related events or circumstances that may have a significant adverse effect on the value of the investment. The risks are initially assessed together with other types of risks as part of the due diligence work before the investment takes place. The various factors are prioritized depending on how important they are for the business, the stakeholders and the expected effect on the investment. A conclusion that there are significant sustainability risks that will not be manageable or limited results in a decision not to invest. Fåhraeus Startup & Growth does not consider the main negative consequences of investment decisions for sustainability factors because, given the fund’s size and investment strategy, it is not possible to carry out reliable due diligence from a cost-benefit perspective. However, the fund continues to evaluate and consider its obligations regarding the investments’ main negative consequences for sustainability factors. Decisions and publications can be reviewed once the technical standards have been adopted and when data and tools for measuring the significant negative consequences regarding unlisted life science and technology companies have been developed and become more efficient. Before making an investment decision, the long-term effects of the investment are taken into account, and the fund avoids taking short-term risks to achieve a profit.